Sign inThe European Commission cleared camizestrant plus a CDK4/6 inhibitor for ER-positive, HER2-negative advanced breast cancer patients who develop an ESR1 mutation before disease progression.
SEC filing
Summit Therapeutics posted $690.7 million in cash at quarter end and highlighted updated HARMONi survival data ahead of a November 14, 2026 FDA decision on ivonescimab.
SEC filing (2)
The company said its first approved clinical sites are now screening participants for the DReAMzz study ahead of planned Phase III development.
SEC filing
The oncology company opened a new at-the-market equity program with J.P. Morgan while warning it lacks enough working capital for the next year.
SEC filing
The company also disclosed that Chief Medical Officer Benjamin Porter-Brown will shift to a consulting role starting July 24, 2026.
SEC filing
The Huntsville biotech disclosed a July 19 amended CEO employment agreement before announcing a July 22 board appointment tied to its Parkinson's program SER-252.
SEC filing (2)
The designation covers imatinib, the active moiety in IKT-001, which Inhibikase is testing in a Phase 3 trial for pulmonary arterial hypertension.
SEC filing
The public benefit corporation appointed the former National Academy of Medicine president to its board effective July 22, 2026, expanding the board to 13 members.
SEC filing
The company signed a distribution agreement with J.P. Morgan Securities allowing it to sell shares over time but carries no obligation to do so.
SEC filing
The all-share merger would move Scancell's melanoma immunotherapy program to Nasdaq while Neuphoria stockholders receive contingent value rights tied to partnered assets.
SEC filing
The company's chief medical officer will speak on changing treatments in bladder cancer at the BTIG Virtual Biotechnology Conference on July 28, 2026.
SEC filing
One patient in the highest-dose cohort hit a RECIST-confirmed partial response and stayed progression-free past seven months, the company said in a July 22, 2026 filing.
SEC filing
The July 18, 2026 agreement, disclosed in an 8-K signed July 22, sets out a five-tranche payment schedule running through June 2027.
SEC filing
The deal pays BioLife holders cash and stock worth $31.00 per share and is expected to close in the fourth quarter of 2026.
SEC filing
The newly filed merger agreement and 8-K detail deal mechanics, closing conditions, and termination terms for the $1.5 billion transaction announced July 22, 2026.
SEC filing
The FDA cleared the ROS1 inhibitor ahead of schedule, marking GSK's first lung cancer approval and its first product from the Nuvalent acquisition.
SEC filing
The company cited faster-than-expected enrollment as the reason for pulling forward its Phase 3 timeline for LB-102.
SEC filing
The deal supplies radium for a study combining carotuximab with Bayer's radiopharmaceutical in bone-involved metastatic castration-resistant prostate cancer.
SEC filing (2)
The Houston-based biotechnology company filed a Form D showing sales toward a $30 million target, with $15.65 million still to be sold.
SEC filing
The Jacksonville Beach, Florida biotechnology company reported $525,000 sold from three investors as of the July 22, 2026 filing.
SEC filing
The neuromuscular disease drug developer expects to close the sale of 18.3 million shares on or about July 23, 2026, with proceeds earmarked to fund clinical programs into the second quarter of 2028.
SEC filing (3)
Douglas Kling will step down as chief operating officer effective August 14, 2026, and is expected to advise on the company's obicetrapib trial work under a separate agreement.
SEC filing
The agency set a PDUFA target action date of May 8, 2027, and does not currently plan an advisory committee meeting.
SEC filing
The San Antonio biotech will combine its flow cytometry work with Pictor's proteomic platform to build tests aimed at guiding personalized asthma and COPD treatment.
SEC filing
The company said the move is meant to help regain Nasdaq compliance and widen its potential investor base.
SEC filing
The provision, tied to an API issue, was booked within inventory write-downs during the June quarter, as cost of revenues and inventory write-downs both rose year over year.
SEC filing
The company, pivoting from failed eye disease trials to an AI platform business, filed a prospectus supplement to sell shares through H.C. Wainwright & Co.
SEC filing
A Form D filed with the SEC shows Cue Biopharma raised nearly $50 million from four investors in an exempt offering dated July 13, 2026.
SEC filing
The financing is set to close alongside a previously disclosed $290 million raise and is meant to fund migraine drug development into 2029, according to a July 22, 2026 filing.
SEC filing
Corvus disclosed in an SEC filing that Clark notified the company of his plan to step down from the board after more than nine years of service.
SEC filing
The clinical research organization posted 17.2% revenue growth and $795.7 million in net new business awards, while narrowing its 2026 revenue guidance range.
SEC filing
Tempest Therapeutics will work with China's Senlang Biotechnology to test TPST-4003 in myasthenia gravis and multiple sclerosis patients starting late 2026.
SEC filing
The San Francisco biotech reported a first sale date of July 10, 2026, and $400,000 raised from a single investor.
SEC filing
Trinity Biotech plans an equity investment in Latch Medical as the two companies explore linking Trinity's CGM+ biosensor with Latch's intradermal delivery device.
SEC filing
Supernus Pharmaceuticals will report second-quarter 2026 financial and business results after market close on August 4, 2026, followed by a management conference call.
SEC filing
Keros said Regnante will leave August 3, 2026, with Corporate Controller Annita Tanini stepping in as interim finance chief the next day.
SEC filing